CDMO Platform "cdmo.jp" Launched Domestically and Internationally – Supporting Drug Discovery Ventures and Pharmaceutical Companies in CDMO Selection
NQ Score
92/100
AI Summary (NQ-processed)
The General Incorporated Association CDMO Association has officially launched "cdmo.jp," a B2B platform designed to organize and compare domestic and international CDMO information. It supports drug discovery ventures and pharmaceutical companies in selecting optimal CDMO partners. Experts from the CDMO industry provide information based on technology, development stages, manufacturing systems, and service areas. Representative Motoichi Doi stated the aim is to create an environment where drug discovery personnel can confidently choose partners.
AI analysis data is not yet available.
Frequently Asked Questions
- Q: What kind of platform is cdmo.jp?
- A: cdmo.jp is a B2B platform that helps drug discovery ventures and pharmaceutical companies select optimal CDMO (Contract Development and Manufacturing Organization) partners by organizing and comparing information on domestic and international CDMOs.
- Q: What problems does cdmo.jp solve?
- A: It addresses challenges faced by the drug discovery field in CDMO selection, such as difficulty grasping the overall landscape of global CDMOs, understanding differences in technical capabilities and service areas, and finding overseas CDMOs when domestic options are insufficient.